Teva Pharmaceuticals Presents 4th Interim Analysis Of PEARL Migraine Prevention Study At EAN Congress; New Sub-Analysis Highlights Potential Negative Impact Of Treatment Pauses On Patient Outcomes
Teva Pharmaceutical Industries Limited Sponsored ADR +2.63% Pre
Teva Pharmaceutical Industries Limited Sponsored ADR TEVA | 18.37 18.37 | +2.63% 0.00% Pre |
- 4th interim analysis of PEARL real world migraine prevention study presented at 10th European Association of Neurology (EAN) congress in Helsinki
- New sub-analysis of PEARL data highlights potential negative impact of treatment pauses on patient outcomes1
- Sub-analysis exploring impact of treatment cessation and reinitiation on migraine prevention suggests potential rise in migraine attacks and diminished treatment effectiveness upon reinitiation1